U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test
Advertisement
Epigenomics AG announced that Quest Diagnostics Incorporated successfully completed the clinical validation of its Septin9-based laboratory-developed test for aiding the detection of colorectal cancer. Under terms of a license agreement between the companies for Epigenomics' proprietary DNA methylation biomarker Septin9, Epigenomics will receive a milestone payment from Quest Diagnostics upon reaching this milestone. The amount of the payment was not disclosed.
"Validation of our Septin9 laboratory-developed test is an important step forward in providing a test that physicians can use to help them identify patients with colorectal cancer," said Jay G. Wohlgemuth, M.D., Vice President of Science and Innovation, Quest Diagnostics. "We intend to release the test in the U.S. later this year."
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Global Pharmaceutical companies expect hard price competition in the rising Biosimilars segment - Bi-annual survey among more than 80 executives from globally active pharmaceutical companies based in 16 countries and spread over four continents
Metobolomics uncovers key indicators of nonalcoholic fatty liver disease - Impaired oxidation in liver associated with progression to NASH
Converting carbon dioxide into useful chemicals with the help of bacteria and solar power - How electrolysis and fermentation can be combined in one system
Agilent Technologies Presents Thought Leader Award to Lipidomics Expert Dr. Jules Griffin - Cambridge Researcher to Further Studies of Obesity, Fatty Liver Disease
3D images display plant organs down to the smallest detail - Intelligent software for a better understanding of plant tissue development
Antibiotic treatment increases the severity of asthma in young mice
Children with rare, incurable brain disease improve after gene therapy
